

Andrew H Wei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5991230/publications.pdf>

Version: 2024-02-01

272
papers

26,478
citations

25034

57
h-index

6836

155
g-index

281
all docs

281
docs citations

281
times ranked

20962
citing authors

#	ARTICLE	IF	CITATIONS
1	Enasidenib vs conventional care in older patients with late-stage mutant- <i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> , 2023, 141, 156-167.	1.4	27
2	Clonal hematopoiesis, myeloid disorders and <i>BAX</i> -mutated myelopoiesis in patients receiving venetoclax for CLL. <i>Blood</i> , 2022, 139, 1198-1207.	1.4	34
3	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 236-250.	0.4	10
4	Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system. <i>Leukemia Research</i> , 2022, 112, 106748.	0.8	2
5	Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. <i>Cancer Discovery</i> , 2022, 12, 774-791.	9.4	18
6	Evolution of Therapy for Older Patients With Acute Myeloid Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> 2023; 29(1): 10-18. doi: 10.1007/s12031-022-00900-0	2.6	2
7	Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. <i>Blood</i> , 2022, 139, 2145-2155.	1.4	38
8	Venetoclax exposureâ€ efficacy and exposureâ€ safety relationships in patients with treatmentâ€naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. <i>Hematological Oncology</i> , 2022, 40, 269-279.	1.7	13
9	Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 2744-2752.	7.0	43
10	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. <i>Cancer Discovery</i> , 2022, 12, 1560-1579.	9.4	13
11	Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, asâ€mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2022, 63, 463-467.	1.3	13
12	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	6.2	12
13	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. <i>Blood Advances</i> , 2022, , .	5.2	13
14	Enhancing our chances of picking a winner in higherâ€risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2022, , .	2.5	0
15	Outcomes following venetoclaxâ€based treatment in therapyâ€related myeloid neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 1013-1022.	4.1	7
16	Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 3879-3883.	5.2	25
17	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	5
18	Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 568-583.	3.8	10

#	ARTICLE	IF	CITATIONS
19	Overall survival by <i>IDH2</i> mutant allele (R140 or R172) in patients with late-stage mutant-<i>IDH2</i> relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.. Journal of Clinical Oncology, 2022, 40, 7005-7005.	1.6	3
20	Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.. Journal of Clinical Oncology, 2022, 40, TPS7068-TPS7068.	1.6	0
21	Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. Leukemia and Lymphoma, 2022, 63, 2731-2734.	1.3	0
22	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	1.4	814
23	Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-<i>IDH2</i> relapsed or refractory acute myeloid leukemia (R/R AML).. Journal of Clinical Oncology, 2022, 40, 7032-7032.	1.6	0
24	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 2022, 140, 1345-1377.	1.4	805
25	The Patientsâ€™ Perspective: Hematological Cancer Patientsâ€™ Experiences of Adverse Events as Part of Care. Journal of Patient Safety, 2021, 17, e387-e392.	1.7	9
26	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia, 2021, 35, 62-74.	7.2	63
27	Venetoclax induces rapid elimination of <i>NPM1</i> mutant measurable residual disease in combination with lowâ€‘intensity chemotherapy in acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1026-1030.	2.5	63
28	Outcomes and health care utilization of older patients with acute myeloid leukemia. Journal of Geriatric Oncology, 2021, 12, 243-249.	1.0	6
29	Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML). Leukemia and Lymphoma, 2021, 62, 489-491.	1.3	0
30	Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. Pathology, 2021, 53, 487-492.	0.6	0
31	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term followâ€‘up from a phase 1b study. American Journal of Hematology, 2021, 96, 208-217.	4.1	95
32	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITDâ€‘Driven Acute Myeloid Leukemia. Cancer Discovery, 2021, 11, 1582-1599.	9.4	35
33	Future Developments: Novel Agents. Hematologic Malignancies, 2021, , 293-315.	0.2	1
34	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia, 2021, 35, 2220-2231.	7.2	20
35	When Azoles Cannot Be Used: The Clinical Effectiveness of Intermittent Liposomal Amphotericin Prophylaxis in Hematology Patients. Open Forum Infectious Diseases, 2021, 8, ofab113.	0.9	8
36	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia, 2021, 35, 2539-2551.	7.2	51

#	ARTICLE	IF	CITATIONS
37	Taking aim at IDH in fitter patients with AML. Blood, 2021, 137, 1706-1707.	1.4	0
38	Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.. Journal of Clinical Oncology, 2021, 39, 7011-7011.	1.6	3
39	Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.. Journal of Clinical Oncology, 2021, 39, 7041-7041.	1.6	0
40	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood, 2021, 137, 2721-2735.	1.4	75
41	Towards precision medicine for AML. Nature Reviews Clinical Oncology, 2021, 18, 577-590.	27.6	138
42	Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) IDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.. Journal of Clinical Oncology, 2021, 39, 7006-7006.	1.6	8
43	COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 2021, 51, 763-768.	0.8	12
44	Fitness for intensive chemotherapy: a continuing conundrum. Blood, 2021, 138, 356-358.	1.4	1
45	Estimating the Productivity Impact of Acute Myeloid Leukemia in Australia Between 2020 and 2029, Using a Novel Work Utility Measure: The Productivity-Adjusted Life Year (PALY). JCO Oncology Practice, 2021, 17, e1803-e1810.	2.9	2
46	Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. Japanese Journal of Clinical Oncology, 2021, 51, 1372-1382.	1.3	2
47	BCL2 and MCL1 inhibitors for hematologic malignancies. Blood, 2021, 138, 1120-1136.	1.4	78
48	The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes. Future Oncology, 2021, 17, 2563-2571.	2.4	2
49	Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?. Leukemia and Lymphoma, 2021, 62, 3073-3077.	1.3	0
50	Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUIAZAR AML-001 trial. Journal of Hematology and Oncology, 2021, 14, 133.	17.0	13
51	FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue. Haematologica, 2021, , .	3.5	0
52	Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer Medicine, 2021, 10, 6336-6343.	2.8	6
53	BCL-2 Inhibition in MDS. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S104-S106.	0.4	0
54	Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2742-2748.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. <i>Haematologica</i> , 2021, 106, 3240-3244.	3.5	6
56	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 580-597.	0.4	28
57	Clinical impact of <i>NPM1</i> -mutant molecular persistence after chemotherapy for acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5107-5111.	5.2	25
58	6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2021, 11, 163.	6.2	17
59	An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. <i>Blood Advances</i> , 2021, 5, 5574-5583.	5.2	6
60	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1597-1608.	10.7	90
61	New Drugs Bringing New Challenges to AML: A Brief Review. <i>Journal of Personalized Medicine</i> , 2021, 11, 1003.	2.5	5
62	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <i>Lancet Haematology</i> , the, 2021, 8, e922-e933.	4.6	27
63	A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1261-1261.	1.4	1
64	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. <i>Blood</i> , 2021, 138, 36-36.	1.4	0
65	High Sensitivity Detection of <i>FLT3</i> -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2364-2364.	1.4	0
66	Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2021, 138, 1283-1283.	1.4	3
67	Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission. <i>Internal Medicine Journal</i> , 2021, 51, 1954-1958.	0.8	0
68	An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 368-368.	1.4	1
69	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. <i>Blood</i> , 2021, 138, 3677-3677.	1.4	5
70	Outcomes for Patients with Late-Stage Mutant-IDH2 (m-IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial. <i>Blood</i> , 2021, 138, 1243-1243.	1.4	9
71	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1204-1223.	13.2	42
72	A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3426-3426.	1.4	9

#	ARTICLE	IF	CITATIONS
73	Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax. <i>Blood</i> , 2021, 138, 267-267.	1.4	0
74	Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax Combined with Hypomethylating Agents. <i>Blood</i> , 2021, 138, 224-224.	1.4	16
75	A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3424-3424.	1.4	1
76	Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant <i>IDH2</i> (m <i>IDH2</i>) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC). <i>Blood</i> , 2021, 138, 1244-1244.	1.4	1
77	Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory <i>mIDH1</i> Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2351-2351.	1.4	3
78	Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. <i>Blood</i> , 2021, 138, 4669-4669.	1.4	10
79	OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 2314-2314.	1.4	1
80	Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with <i>mIDH1</i> Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 698-698.	1.4	7
81	A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). <i>Blood</i> , 2021, 138, 2350-2350.	1.4	4
82	Treatment practice and outcomes in <i>FLT3</i> -mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. <i>Leukemia and Lymphoma</i> , 2020, 61, 848-854.	1.3	3
83	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	5.2	34
84	Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3506-3517.	1.6	112
85	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	27.0	1,407
86	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	4.6	56
87	Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models. <i>Blood Advances</i> , 2020, 4, 5062-5077.	5.2	6
88	New directions for emerging therapies in acute myeloid leukemia: the next chapter. <i>Blood Cancer Journal</i> , 2020, 10, 107.	6.2	96
89	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 2020, 383, 2526-2537.	27.0	265
90	AML-062: Long-Term Follow-Up of a Phase 1/2 Study of Venetoclax (VEN) Plus Low-Dose Cytarabine (LDAC) in Previously Untreated Older Adults with Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S178.	0.4	2

#	ARTICLE	IF	CITATIONS
91	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. <i>Blood Advances</i> , 2020, 4, 1131-1144.	5.2	102
92	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. <i>Blood Advances</i> , 2020, 4, 2762-2767.	5.2	28
93	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 807-815.	2.4	53
94	MDM2 inhibition: an important step forward in cancer therapy. <i>Leukemia</i> , 2020, 34, 2858-2874.	7.2	207
95	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , 2020, 44, 100672.	5.7	135
96	Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells. <i>European Journal of Haematology</i> , 2020, 105, 247-254.	2.2	8
97	How I treat acute myeloid leukemia in the era of new drugs. <i>Blood</i> , 2020, 135, 85-96.	1.4	172
98	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	1.4	127
99	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. <i>Blood</i> , 2020, 135, 791-803.	1.4	412
100	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations. <i>Blood</i> , 2020, 136, 8-10.	1.4	11
101	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. <i>Blood</i> , 2020, 136, 1-2.	1.4	54
102	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 7-8.	1.4	13
103	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	1.4	4
104	Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study. <i>Blood</i> , 2020, 136, 55-57.	1.4	40
105	CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial. <i>Blood</i> , 2020, 136, 32-33.	1.4	12
106	The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16). <i>Blood</i> , 2020, 136, 16-18.	1.4	3
107	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. <i>Blood</i> , 2020, 135, 2137-2145.	1.4	470
108	Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML). <i>Journal of Clinical Oncology</i> , 2020, 38, 7501-7501.	1.6	29

#	ARTICLE	IF	CITATIONS
109	A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.. Journal of Clinical Oncology, 2020, 38, 7511-7511.	1.6	10
110	Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.. Journal of Clinical Oncology, 2020, 38, 7513-7513.	1.6	2
111	Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC).. Journal of Clinical Oncology, 2020, 38, 7533-7533.	1.6	4
112	Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.. Journal of Clinical Oncology, 2020, 38, 7531-7531.	1.6	0
113	CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.. Journal of Clinical Oncology, 2020, 38, 7530-7530.	1.6	1
114	Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. Blood, 2020, 136, 52-52.	1.4	0
115	Peripheral Blood CD34+ Donor Chimerism Is Superior to CD3+ Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Blood, 2020, 136, 47-48.	1.4	0
116	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. Blood, 2020, 136, 40-42.	1.4	7
117	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Blood, 2020, 136, 33-35.	1.4	1
118	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. Journal of Clinical Oncology, 2019, 37, 2632-2642.	1.6	77
119	BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15469-15474.	7.1	31
120	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. Cell Stem Cell, 2019, 25, 258-272.e9.	11.1	60
121	Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?. Cancer Discovery, 2019, 9, 998-1000.	9.4	5
122	Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia. Journal of Clinical Oncology, 2019, 37, 1785-1789.	1.6	2
123	New drugs creating new challenges in acute myeloid leukemia. Genes Chromosomes and Cancer, 2019, 58, 903-914.	2.8	39
124	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	21.4	97
125	Maintenance therapy for AML: are we there yet?. Blood, 2019, 133, 1390-1392.	1.4	8
126	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology, 2019, 37, 1277-1284.	1.6	494

#	ARTICLE	IF	CITATIONS
127	Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2214-2222.	1.3	40
128	Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 3-12.	1.7	12
129	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 905-917.	7.2	126
130	Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. <i>Blood</i> , 2019, 133, 7-17.	1.4	1,254
131	Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propensity Score Matching Analysis Using Data from the AG221-C-001 Trial and Two Data Sources from France and Germany. <i>Blood</i> , 2019, 134, 3893-3893.	1.4	1
132	Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2648-2648.	1.4	3
133	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 231-231.	1.4	23
134	Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. <i>Blood</i> , 2019, 134, 674-674.	1.4	15
135	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 568-568.	1.4	43
136	A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART [®] Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2662-2662.	1.4	11
137	Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study. <i>Blood</i> , 2019, 134, 462-462.	1.4	5
138	Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3897-3897.	1.4	5
139	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE [®] (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 833-833.	1.4	55
140	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 570-570.	1.4	64
141	Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. <i>Blood</i> , 2019, 134, 643-643.	1.4	37
142	The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. <i>Blood</i> , 2019, 134, LBA-3-LBA-3.	1.4	68
143	MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7063-TPS7063.	1.6	8
144	Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML. <i>Blood</i> , 2019, 134, 3930-3930.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML. <i>Cell Stem Cell</i> , 2018, 22, 64-77.e6.	11.1	249
146	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , 2018, 19, 216-228.	10.7	551
147	Prognostic markers in core-binding factor <scp>AML</scp> and improved survival with multiple consolidation cycles of intermediate- to high-dose cytarabine. <i>European Journal of Haematology</i> , 2018, 101, 174-184.	2.2	9
148	Time to repeat and replace response criteria for acute myeloid leukemia?. <i>Blood Reviews</i> , 2018, 32, 416-425.	5.7	51
149	Phase 1b study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 493-496.	1.3	5
150	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. <i>Leukemia</i> , 2018, 32, 303-312.	7.2	123
151	Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014. <i>Internal Medicine Journal</i> , 2018, 48, 822-829.	0.8	7
152	BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. <i>Cancer Cell</i> , 2018, 34, 879-891.	16.8	250
153	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. <i>Cancer Discovery</i> , 2018, 8, 1582-1597.	9.4	310
154	Cytogenetic and Molecular Drivers of Outcome with Venetoclax-Based Combination Therapies in Treatment-Naïve Elderly Patients with Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S202.	0.4	5
155	Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies. <i>Blood Cancer Journal</i> , 2018, 8, 84.	6.2	5
156	High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 68.	6.2	36
157	FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 2800-2800.	1.4	6
158	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Aynndrome (MDS): Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 1452-1452.	1.4	16
159	Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. <i>Blood</i> , 2018, 132, 285-285.	1.4	29
160	Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. <i>Blood</i> , 2018, 132, 284-284.	1.4	30
161	Durable response with venetoclax in combination with decitabine or azacitidine in elderly patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7010-7010.	1.6	7
162	Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7082-TPS7082.	1.6	3

#	ARTICLE	IF	CITATIONS
163	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	1.4	0
164	Improving the Transition to Palliative Care for Patients With Acute Leukemia. Cancer Nursing, 2017, 40, E17-E23.	1.5	4
165	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2017, 376, 836-847.	27.0	1,443
166	â€œDid He Who Made the Lamb Make Thee?â€™ New Developments in Treating the â€œFearful Symmetryâ€™ of Acute Myeloid Leukemia. Trends in Molecular Medicine, 2017, 23, 264-281.	6.7	4
167	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. New England Journal of Medicine, 2017, 377, 454-464.	27.0	1,628
168	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood, 2017, 129, 2882-2895.	1.4	74
169	Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia. British Journal of Haematology, 2017, 177, 328-330.	2.5	4
170	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	1.4	4,375
171	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood, 2017, 129, 771-782.	1.4	67
172	Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood, 2017, 130, 2469-2474.	1.4	110
173	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 1678-1685.	1.6	14
174	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. Blood, 2017, 130, 890-890.	1.4	41
175	The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget, 2017, 8, 52269-52280.	1.8	20
176	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology, 2016, 12, 293-302.	2.4	36
177	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia Research, 2016, 50, 123-131.	0.8	50
178	The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Science Translational Medicine, 2016, 8, 339ra69.	12.4	140
179	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 2016, 538, 477-482.	27.8	830
180	Isavuconazole as salvage therapy for mucormycosis. Medical Mycology Case Reports, 2016, 11, 36-39.	1.3	34

#	ARTICLE	IF	CITATIONS
181	Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. <i>Cancer Cell</i> , 2016, 29, 145-158.	16.8	93
182	PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia. <i>Cell Death and Differentiation</i> , 2016, 23, 1049-1059.	11.2	15
183	The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. <i>Leukemia</i> , 2016, 30, 163-172.	7.2	69
184	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 102-102.	1.4	40
185	Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7007-7007.	1.6	22
186	Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7009-7009.	1.6	33
187	Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML. <i>Blood</i> , 2016, 128, 2877-2877.	1.4	0
188	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. <i>Blood</i> , 2016, 128, 338-338.	1.4	0
189	Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. <i>Haematologica</i> , 2015, 100, 914-926.	3.5	51
190	Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, E219-20.	4.1	2
191	Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation. <i>Transfusion</i> , 2015, 55, 2709-2713.	1.6	13
192	Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2015, 169, 199-210.	2.5	29
193	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 1025-1036.	10.7	129
194	Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML. <i>Blood</i> , 2015, 125, 2815-2824.	1.4	47
195	Protocol of a multi-centre randomised controlled trial of a web-based information intervention with nurse-delivered telephone support for haematological cancer patients and their support persons. <i>BMC Cancer</i> , 2015, 15, 295.	2.6	17
196	Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6280-6296.	3.0	34
197	ABT-199 partners with azacitidine to contest myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2015, 56, 8-9.	1.3	1
198	Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre. <i>Blood</i> , 2015, 126, 5543-5543.	1.4	1

#	ARTICLE	IF	CITATIONS
199	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) Placebo-Controlled Double-Blind Trial (CALGB 10603/PATENT/ALLIANCE-1). Blood, 2015, 126, 6-6.	1.4	104
200	An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.. Journal of Clinical Oncology, 2015, 33, TPS7097-TPS7097.	1.6	0
201	Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia. Blood, 2015, 126, 2599-2599.	1.4	0
202	Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer Journal, 2014, 4, e170-e170.	6.2	80
203	Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients. Clinical Cancer Research, 2014, 20, 724-735.	7.0	76
204	Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia. Blood Cancer Journal, 2014, 4, e237-e237.	6.2	3
205	Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma. Blood Cancer Journal, 2014, 4, e213-e213.	6.2	10
206	Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia. Internal Medicine Journal, 2014, 44, 757-763.	0.8	8
207	Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. American Journal of Hematology, 2014, 89, 795-802.	4.1	63
208	Author reply. Internal Medicine Journal, 2014, 44, 825-825.	0.8	0
209	Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion in Hematology, 2014, 21, 102-113.	2.5	9
210	Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Practice and Research in Clinical Haematology, 2014, 27, 39-52.	1.7	13
211	Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. Leukemia, 2014, 28, 2005-2015.	7.2	43
212	KB004, a Novel Non-Fucosylated Humanized Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies. Blood, 2014, 124, 3756-3756.	1.4	3
213	Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting. Blood, 2014, 124, 988-988.	1.4	2
214	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. Blood, 2014, 124, 69-69.	1.4	0
215	Cardiac Imaging in FIP1L1-PDGFR. Journal of the American College of Cardiology, 2013, 62, 1304.	2.8	1
216	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	1.4	53

#	ARTICLE	IF	CITATIONS
217	Improving the transition of highly complex patients into the community: impact of a pharmacist in an allogeneic stem cell transplant (SCT) outpatient clinic. <i>Supportive Care in Cancer</i> , 2013, 21, 3491-3495.	2.2	23
218	Effectiveness of a single fixed dose of rasburicase 3â€‰mg in the management of tumour lysis syndrome. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 565-568.	2.4	20
219	Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-X _L . <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5514-5540.	6.4	60
220	Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 675-676.	1.3	2
221	Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. <i>Leukemia and Lymphoma</i> , 2013, 54, 336-341.	1.3	13
222	Utility of a clinical risk score to identify high-risk patients with <i>de novo</i> acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. <i>British Journal of Haematology</i> , 2013, 160, 861-863.	2.5	8
223	Methylation of <i>KLF5</i> contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. <i>British Journal of Haematology</i> , 2013, 161, 884-888.	2.5	18
224	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 2611-2619.	4.1	88
225	High-dose cytarabine (24â€‰g/m ²) in combination with idarubicin (HiDACâ€‰3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. <i>Internal Medicine Journal</i> , 2013, 43, 294-297.	0.8	10
226	GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations. <i>Leukemia</i> , 2013, 27, 1588-1592.	7.2	22
227	Protein Kinase Activity of Phosphoinositide 3-Kinase Regulates Cytokine-Dependent Cell Survival. <i>PLoS Biology</i> , 2013, 11, e1001515.	5.6	19
228	A Phase I Study Of KB004, a Novel Non-Fucosylated humanized Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies. <i>Blood</i> , 2013, 122, 3838-3838.	1.4	3
229	Fli-1 Overexpression in Hematopoietic Progenitors Deregulates T Cell Development and Induces Pre-T Cell Lymphoblastic Leukaemia/Lymphoma. <i>PLoS ONE</i> , 2013, 8, e62346.	2.5	24
230	Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality. <i>Blood</i> , 2013, 122, 2128-2128.	1.4	2
231	Puma Is The Critical BH3-Only Protein Mediating Apoptosis In The Nup98-HoxD13 (NHD13) Mouse Model Of Human MDS. <i>Blood</i> , 2013, 122, 1563-1563.	1.4	0
232	Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. <i>Genes and Development</i> , 2012, 26, 120-125.	5.9	344
233	Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis. <i>Leukemia and Lymphoma</i> , 2012, 53, 1225-1229.	1.3	3
234	Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. <i>Leukemia</i> , 2012, 26, 362-365.	7.2	4

#	ARTICLE	IF	CITATIONS
235	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. <i>Blood</i> , 2012, 120, 889-889.	1.4	4
236	Stage I findings of a two-stage phase II study to assess the efficacy, safety, and tolerability of barasertib (AZD1152) compared with low-dose cytosine arabinoside (LDAC) in elderly patients (pts) with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2012, 30, 6527-6527.	1.6	1
237	Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival.. <i>Blood</i> , 2012, 120, 2396-2396.	1.4	0
238	A Regulatory Promoter Polymorphism and Hypermethylation of Intron 1 Are Associated with Reduced Expression of KLF5 and Inferior Survival in AML. <i>Blood</i> , 2012, 120, 3508-3508.	1.4	0
239	The epigenomics revolution in myelodysplasia: a clinico-pathological perspective. <i>Pathology</i> , 2011, 43, 536-546.	0.6	12
240	Use of risk stratification to guide ambulatory management of neutropenic fever. <i>Internal Medicine Journal</i> , 2011, 41, 82-89.	0.8	30
241	Use of antibacterial prophylaxis for patients with neutropenia. <i>Internal Medicine Journal</i> , 2011, 41, 102-109.	0.8	45
242	Salvaging AML with CLAG: Novel option, or more of the same?. <i>Leukemia Research</i> , 2011, 35, 297-298.	0.8	2
243	Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study. <i>Blood</i> , 2011, 118, 1529-1529.	1.4	1
244	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. <i>Blood</i> , 2011, 118, 2599-2599.	1.4	7
245	A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results. <i>Blood</i> , 2011, 118, 4893-4893.	1.4	4
246	Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,. <i>Blood</i> , 2011, 118, 3631-3631.	1.4	0
247	A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,. <i>Blood</i> , 2011, 118, 3625-3625.	1.4	1
248	Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,. <i>Blood</i> , 2011, 118, 3540-3540.	1.4	0
249	Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 926-927.	5.7	56
250	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. <i>PLoS Pathogens</i> , 2010, 6, e1001236.	4.7	99
251	Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up. <i>Bone Marrow Transplantation</i> , 2010, 45, 1154-1160.	2.4	4
252	Revisiting late relapses in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 735-736.	1.3	2

#	ARTICLE	IF	CITATIONS
253	A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML. Blood, 2010, 116, 3299-3299.	1.4	6
254	Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study. Blood, 2010, 116, 3301-3301.	1.4	1
255	Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 1964-1968.	1.3	4
256	New insights into the haemostatic function of platelets. British Journal of Haematology, 2009, 147, 415-430.	2.5	81
257	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the gallbladder. Surgical Practice, 2008, 12, 137-141.	0.2	1
258	Boosting platelet production. Nature Medicine, 2008, 14, 917-918.	30.7	6
259	Prosthetic pulmonary valve thrombosis in pregnancy successfully treated with thrombolysis. Internal Medicine Journal, 2008, 38, 142-143.	0.8	4
260	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17961-17966.	7.1	137
261	Bortezomib: Putting mantle cell lymphoma on death row. Leukemia and Lymphoma, 2008, 49, 657-658.	1.3	5
262	Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leukemia and Lymphoma, 2007, 48, 212-213.	1.3	18
263	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8071-8076.	7.1	195
264	Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene. European Journal of Haematology, 2007, 79, 363-366.	2.2	14
265	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10, 389-399.	16.8	1,149
266	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes and Development, 2005, 19, 1294-1305.	5.9	1,071
267	Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Molecular Cell, 2005, 17, 393-403.	9.7	1,639
268	Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 469-477.	1.1	26
269	CD 138 Immunostaining of Bone Marrow Trephine Specimens Is the Most Sensitive Method for Quantifying Marrow Involvement in Patients with Plasma Cell Dyscrasias.. Blood, 2005, 106, 5071-5071.	1.4	0
270	Bone marrow immunohistology of plasma cell neoplasms. Journal of Clinical Pathology, 2003, 56, 406-411.	2.0	38

#	ARTICLE	IF	CITATIONS
271	Granulocyte colony-stimulating factorâ€‘induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/ β^2 + thalassemia. Blood, 2001, 97, 3998-3999.	1.4	101
272	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	1.3	3